VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2004
The purpose of this study is to evaluate the safety and effectiveness of VELCADE when given in combination with rituximab in patients with Relapsed or Refractory Indolent B-Cell Lymphoma. This study will investigate if treatment with VELCADE and rituximab increases the time it takes your lymphoma to get worse.
Epistemonikos ID: 94a68cd5b9af8d222716562f9cec43c3e2b27311
First added on: May 04, 2024